Third Quarter 2025 Results / Quarterly Reports

Bayer Q3 2025 Media Update

Group sales at 9.660 billion euros (Fx & portfolio adj. plus 0.9 percent)
EBITDA before special items increases 20.8 percent to 1.511 billion euros
Crop Science posts higher sales (Fx & portfolio adj.) and strong earnings growth
Pharmaceuticals sales at prior-year level (Fx & portfolio adj.), earnings down
Consumer Health reports moderate sales growth (Fx & portfolio adj.) and stable earnings
Core earnings per share rise 137.5 percent to 0.57 euros
Net income at minus 963 million euros, impacted by special charges for litigations
Free cash flow declines to 596 million euros
Net financial debt reduced slightly to 32.708 billion euros
Adjustment to 2025 sales expectation at Consumer Health, Group guidance confirmed